Otros idiomas Polaris Group

Acciones

6550

KYG7171A1085

Precio de cierre Taiwan S.E. Otros sitios de cotización 00:00:00 25/06/2024			Varia. Cinco días.	Varia. 1 de enero.
71,3 ^TWD	-0,42 %		+0,85 %	-5,69 %

15/05	El Grupo Polaris retira voluntariamente de la FDA el protocolo de ensayo clínico de fase III para el cáncer de hígado	CI
14/05	Polaris Group anuncia el cambio del miembro del Comité de Compensación	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA	15/05
Polaris Group Announces Change of the Member of Compensation Committee	14/05
Polaris Group Announces Change of the Member of Audit Committee	03/05
Polaris Group acquired an additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	23/12
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth	22/12
Polaris Group Announces the Appointment of K Evin Wu	21/12
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	21/12
Polaris Group agreed to acquire additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	21/12
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	04/12
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	04/12
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study	30/11
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan	29/11
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	17/11
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	17/11
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11/11
Polaris Group announced a financing transaction	06/10/23
Polaris Group Appoints K.C. Tsai as Compensation Committee Member	26/09/23
TDW HK Limited announced that it has received $17 million in funding from Polaris Group	26/09/23
Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member	29/08/23
Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director	29/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Polaris Group

Acciones

6550

KYG7171A1085

Otros idiomas

Filtros